$ASMB
Assembly Biosciences Inc

2013 Q3 Form 10-Q Financial Statement

#000114420413044388 Filed on August 09, 2013

View on sec.gov

Income Statement

Concept 2013 Q3 2013 Q2 2012 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.180M $1.300M $1.320M
YoY Change 0.0% -1.52% -65.26%
% of Gross Profit
Research & Development $3.753M $3.508M $6.162M
YoY Change -10.38% -43.06% 98.8%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00 $0.00
YoY Change
% of Gross Profit
Operating Expenses $3.753M $3.508M $6.162M
YoY Change -10.38% -43.06% 98.8%
Operating Profit -$4.933M -$4.809M -$7.478M
YoY Change -8.14% -35.7% 8.36%
Interest Expense $50.00K $60.00K $10.00K
YoY Change 400.0% 500.0% -84.83%
% of Operating Profit
Other Income/Expense, Net $51.27K $0.00 $0.00
YoY Change
Pretax Income -$4.880M -$4.750M -$7.470M
YoY Change -8.96% -36.41% 7.33%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$4.882M -$4.752M -$7.470M
YoY Change -8.84% -36.39% 7.3%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$1.226M -$1.206M -$2.953M
COMMON SHARES
Basic Shares Outstanding 19.60M shares 12.49M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2013 Q3 2013 Q2 2012 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $32.20M $33.50M $28.80M
YoY Change 36.44% 16.32% 152.63%
Cash & Equivalents $32.22M $33.49M $28.84M
Short-Term Investments
Other Short-Term Assets $134.8K $177.5K $157.1K
YoY Change 34.78% 13.01% 57.09%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $32.36M $33.67M $29.00M
YoY Change 36.53% 16.09% 152.18%
LONG-TERM ASSETS
Property, Plant & Equipment $7.632K $9.329K $9.375K
YoY Change -0.49%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $7.632K $9.329K $9.375K
YoY Change -0.49%
TOTAL ASSETS
Total Short-Term Assets $32.36M $33.67M $29.00M
Total Long-Term Assets $7.632K $9.329K $9.375K
Total Assets $32.37M $33.68M $29.01M
YoY Change 36.56% 16.09% 152.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.280M $2.132M $3.158M
YoY Change 26.68% -32.5% 426.31%
Accrued Expenses $37.42K $453.7K $234.0K
YoY Change -95.32% 93.89% 134.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.300M $2.600M $3.392M
YoY Change -14.81% -23.35% 323.98%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.300M $2.600M $3.392M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $2.318M $2.585M $3.400M
YoY Change -14.16% -23.96% 61.9%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock $20.66K $19.60K $12.92K
YoY Change 51.7%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $30.05M $31.09M $25.62M
YoY Change
Total Liabilities & Shareholders Equity $32.37M $33.68M $29.01M
YoY Change 36.56% 16.09% 152.26%

Cashflow Statement

Concept 2013 Q3 2013 Q2 2012 Q2
OPERATING ACTIVITIES
Net Income -$4.882M -$4.752M -$7.470M
YoY Change -8.84% -36.39% 7.3%
Depreciation, Depletion And Amortization $0.00 $0.00 $0.00
YoY Change
Cash From Operating Activities -$4.650M -$3.380M -$6.940M
YoY Change -11.93% -51.3% 142.66%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$10.00K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$10.00K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $4.166M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 3.390M 0.000 4.720M
YoY Change -100.0% 2045.45%
NET CHANGE
Cash From Operating Activities -4.650M -3.380M -6.940M
Cash From Investing Activities 0.000 -10.00K 0.000
Cash From Financing Activities 3.390M 0.000 4.720M
Net Change In Cash -1.260M -3.390M -2.220M
YoY Change -76.14% 52.7% -15.91%
FREE CASH FLOW
Cash From Operating Activities -$4.650M -$3.380M -$6.940M
Capital Expenditures $0.00 -$10.00K $0.00
Free Cash Flow -$4.650M -$3.370M -$6.940M
YoY Change -11.93% -51.44% 142.66%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Trading Symbol
TradingSymbol
VTUS
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2013Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2013Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
220000 shares
CY2012Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
220000 shares
CY2012Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
dei Document Period End Date
DocumentPeriodEndDate
2013-06-30
dei Amendment Flag
AmendmentFlag
false
CY2012Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7478306 USD
dei Document Type
DocumentType
10-Q
CY2013Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4808759 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-87207534 USD
CY2013Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
19604350 shares
dei Entity Registrant Name
EntityRegistrantName
VENTRUS BIOSCIENCES INC
dei Entity Central Index Key
EntityCentralIndexKey
0001426800
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12584650 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
65160959 USD
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
20754418 USD
CY2013Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
0 USD
CY2012Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1316382 USD
CY2012Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
0 USD
CY2013Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3508450 USD
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-4751888 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-15668363 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-8577727 USD
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
12934 USD
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
110116766 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6117553 USD
CY2013Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1300309 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2460174 USD
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12934350 shares
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12934350 shares
CY2013Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19604350 shares
CY2013Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19604350 shares
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
20754418 USD
CY2013Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
33676769 USD
CY2013Q2 vtus Common Stock Issuable Shares
CommonStockIssuableShares
125000 shares
CY2013Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
33489917 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20489219 USD
CY2013Q2 us-gaap Other Assets Current
OtherAssetsCurrent
177523 USD
CY2012Q4 us-gaap Other Assets Current
OtherAssetsCurrent
59584 USD
CY2013Q2 us-gaap Assets Current
AssetsCurrent
33667440 USD
CY2012Q4 us-gaap Assets Current
AssetsCurrent
20548803 USD
CY2013Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9329 USD
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6841 USD
CY2013Q2 us-gaap Assets
Assets
33676769 USD
CY2012Q4 us-gaap Assets
Assets
20555644 USD
CY2013Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2131673 USD
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1847245 USD
CY2013Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
453710 USD
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
898213 USD
CY2013Q2 us-gaap Liabilities
Liabilities
2585383 USD
CY2012Q4 us-gaap Liabilities
Liabilities
2745458 USD
CY2013Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q2 us-gaap Preferred Stock Value
PreferredStockValue
220 USD
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2013Q2 us-gaap Common Stock Value
CommonStockValue
19604 USD
CY2013Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
131497309 USD
CY2013Q2 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
100794497 USD
CY2012Q4 us-gaap Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
92319514 USD
CY2013Q2 us-gaap Stockholders Equity
StockholdersEquity
31091386 USD
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
17810186 USD
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
20555644 USD
CY2013Q2 vtus Common Stock Value Issuable
CommonStockValueIssuable
368750 USD
CY2012Q4 vtus Common Stock Value Issuable
CommonStockValueIssuable
0 USD
CY2012Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6161924 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3083713 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22046575 USD
CY2013Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
56871 USD
CY2012Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
8258 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
102744 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
24439 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
263863 USD
CY2013Q2 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
0 USD
CY2012Q2 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
0 USD
us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
6001496 USD
CY2013Q2 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 USD
CY2012Q2 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2865758 USD
CY2013Q2 us-gaap Interest Expense Other
InterestExpenseOther
0 USD
CY2012Q2 us-gaap Interest Expense Other
InterestExpenseOther
0 USD
us-gaap Interest Expense Other
InterestExpenseOther
4983572 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-13850826 USD
CY2012Q2 us-gaap Net Income Loss
NetIncomeLoss
-7470048 USD
us-gaap Net Income Loss
NetIncomeLoss
-8474983 USD
us-gaap Net Income Loss
NetIncomeLoss
-15643924 USD
us-gaap Net Income Loss
NetIncomeLoss
-100794497 USD
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.24
CY2012Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.59
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.46
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.25
vtus Warrant Issued In Connection With Convertible Notes
WarrantIssuedInConnectionWithConvertibleNotes
0 USD
vtus Warrant Issued In Connection With Convertible Notes
WarrantIssuedInConnectionWithConvertibleNotes
0 USD
CY2013Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
19722482 shares
CY2012Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12627316 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18396384 shares
vtus Stock Issuable During Period Shares Share Based Compensation
StockIssuableDuringPeriodSharesShareBasedCompensation
125000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12518121 shares
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
551417 USD
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 USD
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 USD
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
1087876 USD
us-gaap Other Noncash Expense
OtherNoncashExpense
0 USD
us-gaap Other Noncash Expense
OtherNoncashExpense
0 USD
us-gaap Other Noncash Expense
OtherNoncashExpense
227910 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
117939 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
94956 USD
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
177523 USD
us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
22190 USD
vtus Share Based Compensation Arrangement By Share Based Payment Award Restricted Value Granted In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedValueGrantedInPeriod
59408 USD
vtus Stock Issuable During Period Value Share Based Compensation
StockIssuableDuringPeriodValueShareBasedCompensation
368750 USD
us-gaap Share Based Compensation
ShareBasedCompensation
979575 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1540553 USD
us-gaap Share Based Compensation
ShareBasedCompensation
9751497 USD
vtus Stock Based Compensation Expense For Services
StockBasedCompensationExpenseForServices
22190 USD
vtus Stock Based Compensation Expense For Services
StockBasedCompensationExpenseForServices
292350 USD
vtus Stock Based Compensation Expense For Services
StockBasedCompensationExpenseForServices
4352449 USD
us-gaap Depreciation
Depreciation
2678 USD
us-gaap Depreciation
Depreciation
2083 USD
us-gaap Depreciation
Depreciation
38301 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
0 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
3466010 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-160075 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
878764 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2397846 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7748554 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13025130 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-69566644 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5166 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3240 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
47630 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5166 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3240 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-47630 USD
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
4166494 USD
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
90094079 USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 USD
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
11522380 USD
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0 USD
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0 USD
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
5041953 USD
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0 USD
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0 USD
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
1431603 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
2719380 USD
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
0 USD
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
0 USD
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
1573000 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
730322 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2169762 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20754418 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4896816 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
103104191 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
13000698 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-8131554 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
33489917 USD
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36975434 USD
CY2005Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0 USD
CY2012Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28843880 USD
vtus Supplemental Warrant Issued To Placement Agent And Investors In Private Placement
SupplementalWarrantIssuedToPlacementAgentAndInvestorsInPrivatePlacement
0 USD
vtus Supplemental Warrant Issued To Placement Agent And Investors In Private Placement
SupplementalWarrantIssuedToPlacementAgentAndInvestorsInPrivatePlacement
0 USD
vtus Supplemental Warrant Issued To Placement Agent And Investors In Private Placement
SupplementalWarrantIssuedToPlacementAgentAndInvestorsInPrivatePlacement
341334 USD
vtus Warrant Issued In Connection With Convertible Notes
WarrantIssuedInConnectionWithConvertibleNotes
1166989 USD
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0 USD
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0 USD
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
14003158 USD
us-gaap Interest Paid
InterestPaid
0 USD
us-gaap Interest Paid
InterestPaid
0 USD
us-gaap Interest Paid
InterestPaid
685397 USD
CY2013Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
20800000 USD
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2005-10-07
dei Entity Incorporation State Country Name
EntityIncorporationStateCountryName
Delaware
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5518126 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3154564 shares
us-gaap Use Of Estimates
UseOfEstimates
<div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px 0pt 0.5in; FONT: 10pt Times New Roman, Times, Serif"> <strong>Use of estimates:</strong></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"><font size="2">&#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"><font size="2">&#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Significant estimates inherent in the preparation of the accompanying financial statements include the fair value of stock options and warrants granted to employees, consultants, directors, investors, licensors, placement agents and underwriters.</div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"><font size="2">&#160;</font></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> Additionally, the Company provides a valuation allowance for deferred income tax assets when it is considered more likely than not that all or a portion of such deferred income tax assets will not be realized.</div> </div>
CY2011Q3 us-gaap Deferred Compensation Arrangement With Individual Allocated Share Based Compensation Expense
DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense
300000 USD
CY2011Q3 us-gaap Deferred Compensation Arrangement With Individual Distributions Paid
DeferredCompensationArrangementWithIndividualDistributionsPaid
200000 USD
CY2011Q3 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
9.85
CY2013Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6670000 shares
CY2013Q1 vtus Stock Issued During Period Price Per Share New Issues
StockIssuedDuringPeriodPricePerShareNewIssues
2.50
CY2012 vtus Share Based Compensation Shares Authorized Under Stock Option Plans Grants In Period Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansGrantsInPeriodExercisePriceRangeLowerRangeLimit
3.60
CY2012 vtus Share Based Compensation Shares Authorized Under Stock Option Plans Grants In Period Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansGrantsInPeriodExercisePriceRangeUpperRangeLimit
10.62
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
30000 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y
CY2012 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4200000 USD
us-gaap Preferred Stock Conversion Basis
PreferredStockConversionBasis
Series A preferred stock is convertible into 10 common shares of the Company’s common stock at any time at the holder’s option
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1135000 USD
vtus Restricted Stock Expensed Percentage
RestrictedStockExpensedPercentage
0.25 pure
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1878475 shares
vtus Share Based Compensation Arrangement By Share Based Payment Award Option Vested And Expected To Vest Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionVestedAndExpectedToVestGranted
190000 shares
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2068475 shares
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1597449 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.72
vtus Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Granted Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice
2.94
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.37
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0 USD
CY2013Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2013Q2 vtus Future Stock Based Compensation Expense Year Two
FutureStockBasedCompensationExpenseYearTwo
542162 USD
CY2013Q2 vtus Future Stock Based Compensation Expense Year Three
FutureStockBasedCompensationExpenseYearThree
582623 USD
CY2013Q2 vtus Future Stock Based Compensation Expense Year Four
FutureStockBasedCompensationExpenseYearFour
109617 USD
CY2013Q2 vtus Future Stock Based Compensation Expense Total
FutureStockBasedCompensationExpenseTotal
75423 USD
CY2013Q2 vtus Future Stock Based Compensation Expense Year Five
FutureStockBasedCompensationExpenseYearFive
1309825 USD
CY2012Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
874651 shares
vtus Class Of Warrant Or Right Grants In Period
ClassOfWarrantOrRightGrantsInPeriod
0 shares
vtus Class Of Warrant Or Right Exercised In Period
ClassOfWarrantOrRightExercisedInPeriod
0 shares
CY2013Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
874651 shares
CY2013Q2 vtus Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
874651 shares
CY2012Q4 vtus Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
7.67
CY2013Q2 vtus Class Of Warrant Or Right Grants In Period Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightGrantsInPeriodWeightedAverageExercisePriceOfWarrantsOrRights
0
CY2013Q2 vtus Class Of Warrant Or Right Expired In Period Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExpiredInPeriodWeightedAverageExercisePriceOfWarrantsOrRights
0
CY2013Q2 vtus Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
7.67
CY2013Q2 vtus Class Of Warrant Or Right Exercisable Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisableWeightedAverageExercisePriceOfWarrantsOrRights
7.67

Files In Submission

Name View Source Status
0001144204-13-044388-index-headers.html Edgar Link pending
0001144204-13-044388-index.html Edgar Link pending
0001144204-13-044388.txt Edgar Link pending
0001144204-13-044388-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
R1.htm Edgar Link pending
R1.xml Edgar Link unprocessable
R10.htm Edgar Link pending
R10.xml Edgar Link unprocessable
R11.htm Edgar Link pending
R11.xml Edgar Link unprocessable
R12.htm Edgar Link pending
R12.xml Edgar Link unprocessable
R13.htm Edgar Link pending
R13.xml Edgar Link unprocessable
R14.htm Edgar Link pending
R14.xml Edgar Link unprocessable
R15.htm Edgar Link pending
R15.xml Edgar Link unprocessable
R16.htm Edgar Link pending
R16.xml Edgar Link unprocessable
R17.htm Edgar Link pending
R17.xml Edgar Link unprocessable
R18.htm Edgar Link pending
R18.xml Edgar Link unprocessable
R19.htm Edgar Link pending
R19.xml Edgar Link unprocessable
R2.htm Edgar Link pending
R2.xml Edgar Link unprocessable
R20.htm Edgar Link pending
R20.xml Edgar Link unprocessable
R21.htm Edgar Link pending
R21.xml Edgar Link unprocessable
R22.htm Edgar Link pending
R22.xml Edgar Link unprocessable
R23.htm Edgar Link pending
R23.xml Edgar Link unprocessable
R24.htm Edgar Link pending
R24.xml Edgar Link unprocessable
R25.htm Edgar Link pending
R25.xml Edgar Link unprocessable
R3.htm Edgar Link pending
R3.xml Edgar Link unprocessable
R4.htm Edgar Link pending
R4.xml Edgar Link unprocessable
R5.htm Edgar Link pending
R5.xml Edgar Link unprocessable
R6.htm Edgar Link pending
R6.xml Edgar Link unprocessable
R7.htm Edgar Link pending
R7.xml Edgar Link unprocessable
R8.htm Edgar Link pending
R8.xml Edgar Link unprocessable
R9.htm Edgar Link pending
R9.xml Edgar Link unprocessable
report.css Edgar Link pending
Show.js Edgar Link pending
v351214_10q.htm Edgar Link pending
v351214_ex31-1.htm Edgar Link pending
v351214_ex31-2.htm Edgar Link pending
v351214_ex32-1.htm Edgar Link pending
v351214_ex32-2.htm Edgar Link pending
vtus-20130630.xml Edgar Link completed
vtus-20130630.xsd Edgar Link pending
vtus-20130630_cal.xml Edgar Link unprocessable
vtus-20130630_def.xml Edgar Link unprocessable
vtus-20130630_lab.xml Edgar Link unprocessable
vtus-20130630_pre.xml Edgar Link unprocessable